Navigation Links
Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead's 4th Annual Pain Therapeutics Summit
Date:6/13/2010

Jeffrey Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with Animal Models of Pain?” at Arrowhead’s upcoming 4th Annual Pain Therapeutics Summit, to be held October 4-5, 2010 in Philadelphia, Pennsylvania.

Minneapolis, MN (PRWEB) June 10, 2010 -- Jeffrey Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with Animal Models of Pain?” at Arrowhead’s upcoming 4th Annual Pain Therapeutics Summit, to be held October 4-5, 2010 in Philadelphia, Pennsylvania.

Recent decades have seen an explosion in our understanding of the molecular and cellular underpinnings of pain, but virtually none of this knowledge has resulted in new clinical therapies. Many pain researchers believe that the problem may lie in the existing animal models of pain, which are reliable but much more complex and subtle than is commonly realized, and of questionable clinical relevance.

In addition to the disconnect between clinical symptoms and animal measures, there is a disconnect between the clinical epidemiology of pain and the types of pain being modeled in animals. Dr. Mogil’s presentation, “What’s Wrong with Animal Models of Pain?” will cover recent successes in his laboratory, involving migraine, vestibulodynia, and the development of a facial expression-based pain scale for the mouse (recently published in Nature Methods).

Jeffrey Mogil is currently the E.P. Taylor Professor of Pain Studies and the Canada Research Chair in the Genetics of Pain at McGill University. Dr. Mogil is the author of many major reviews of the subject and is the editor of The Genetics of Pain. He is a recognized authority in the fields of sex differences in pain and analgesia, and pain testing methods in the laboratory mouse. Dr. Mogil is the author of over 150 journal articles and book chapters since 1992, and has given over 190 invited lectures in that same period. He currently serves as a Section Editor (Neurobiology) at the journal Pain.

Now in its 4th year, Arrowhead’s Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics. For more information, go to www.paintherapeuticssummit.com or email us at enquires(at)paintherapeuticsummit(dot)com.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4116614.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
2. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
3. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
4. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
5. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
6. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
7. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
8. Dr. David Wolf, NASA Astronaut and Inventor, to Speak at BioConference Live
9. China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit
10. Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
11. FMC Agricultural Products Executive Bob Trogele Speaks to the Iowa Agribusiness Showcase & Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
(Date:2/3/2016)... 3, 2016   ViaCyte, Inc ., a ... pluripotent stem cell-derived islet replacement therapy for the ... today announced that ViaCyte and Janssen Biotech, Inc., ... & Johnson, have agreed to consolidate the assets ... agreement provides ViaCyte with an exclusive license to ...
(Date:2/3/2016)... NEW BRUNSWICK, N.J. , Feb. 3, 2016 ... 30 grants totaling more than $1 million for ... who are working on health-related research that demonstrates ... , this round of funding for the New ... available for faculty members at these educational institutions— ...
(Date:2/3/2016)... MEDFORD, Mass. , Feb. 3, 2016  Silk Therapeutics, ... A2 financing round. Silk Therapeutics has now raised a total ... progress made by the company. The Series A2 round was ... Foxboro, Massachusetts , with participation from new investors Lear ... Sheri and Roy P. Disney ; Richard Sackler ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces the ... Joey Fatone . Las Vegas , where ... --> Las Vegas , where Joey appeared at ... The new video ad was filmed at the Consumer Electronics Show (CES2016) ... Wocket booth to meet and greet fans. --> ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):